<DOC>
	<DOC>NCT00801866</DOC>
	<brief_summary>to evaluate the efficacy of a single intravitreal bevacizumab (IVB) injection, 0.1mL (2.5mg), against panretinal photocoagulation (PRP)-induced macular thickening and visual disturbance in patients with severe nonproliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR) and good vision</brief_summary>
	<brief_title>Avastin for Post-Photocoagulation Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Patients with Proliferative retinopathy or severe nonproliferative retinopathy BCVA of 20/63 or better (56 ETDRS letters No history of Macular Edema Central Retinal Thickness of 250mics or more Previous treatment. Other ophthalmic diseases. history of Nephropathy, heart diseases and pregnancy Media opacities</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Panretinal Photocoagulation</keyword>
	<keyword>Macular Edema</keyword>
	<keyword>Intravitreal Bevacizumab</keyword>
</DOC>